Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies

Immunotherapy for brain tumors remains elusive, unlike many other cancer types for which it is one of the most promising therapeutic options. Recent studies have comprehensively profiled the immune-landscape of the highly malignant brain tumor, glioblastoma (GBM) in patients and identified novel imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalsa, Jasneet Kaur, Shah, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996275/
https://www.ncbi.nlm.nih.gov/pubmed/33668856
http://dx.doi.org/10.3390/cells10030491
_version_ 1783670081058766848
author Khalsa, Jasneet Kaur
Shah, Khalid
author_facet Khalsa, Jasneet Kaur
Shah, Khalid
author_sort Khalsa, Jasneet Kaur
collection PubMed
description Immunotherapy for brain tumors remains elusive, unlike many other cancer types for which it is one of the most promising therapeutic options. Recent studies have comprehensively profiled the immune-landscape of the highly malignant brain tumor, glioblastoma (GBM) in patients and identified novel immune-modulatory targets. However, given that pre-clinical exploration of potential novel therapeutics is primarily performed in immune-competent mice, it is vital to compare the immune-profiling data obtained from syngeneic mouse GBM models with GBM patient samples. This will pave the way for utilizing appropriate clinically relevant mouse GBM models for evaluating novel immune-therapies in pre-clinical settings. Recent brain tumor immune-profiling studies using state-of-the-art time of flight cytometry (CyTOF) analysis compared different human and mouse GBM types and reported immunological distinctions amongst these mouse models. These studies also contrast the immune phenotype of brain tumor patients with commonly used pre-clinical immune-competent mouse models. In this perspective, we provide the outcomes of very recent brain tumor immune-profiling studies and their implications on designing and translating unique, tumor-subtype specific therapeutics.
format Online
Article
Text
id pubmed-7996275
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79962752021-03-27 Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies Khalsa, Jasneet Kaur Shah, Khalid Cells Opinion Immunotherapy for brain tumors remains elusive, unlike many other cancer types for which it is one of the most promising therapeutic options. Recent studies have comprehensively profiled the immune-landscape of the highly malignant brain tumor, glioblastoma (GBM) in patients and identified novel immune-modulatory targets. However, given that pre-clinical exploration of potential novel therapeutics is primarily performed in immune-competent mice, it is vital to compare the immune-profiling data obtained from syngeneic mouse GBM models with GBM patient samples. This will pave the way for utilizing appropriate clinically relevant mouse GBM models for evaluating novel immune-therapies in pre-clinical settings. Recent brain tumor immune-profiling studies using state-of-the-art time of flight cytometry (CyTOF) analysis compared different human and mouse GBM types and reported immunological distinctions amongst these mouse models. These studies also contrast the immune phenotype of brain tumor patients with commonly used pre-clinical immune-competent mouse models. In this perspective, we provide the outcomes of very recent brain tumor immune-profiling studies and their implications on designing and translating unique, tumor-subtype specific therapeutics. MDPI 2021-02-25 /pmc/articles/PMC7996275/ /pubmed/33668856 http://dx.doi.org/10.3390/cells10030491 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Opinion
Khalsa, Jasneet Kaur
Shah, Khalid
Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
title Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
title_full Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
title_fullStr Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
title_full_unstemmed Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
title_short Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
title_sort immune profiling of syngeneic murine and patient gbms for effective translation of immunotherapies
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996275/
https://www.ncbi.nlm.nih.gov/pubmed/33668856
http://dx.doi.org/10.3390/cells10030491
work_keys_str_mv AT khalsajasneetkaur immuneprofilingofsyngeneicmurineandpatientgbmsforeffectivetranslationofimmunotherapies
AT shahkhalid immuneprofilingofsyngeneicmurineandpatientgbmsforeffectivetranslationofimmunotherapies